Al-Sawaf, O., Robrecht, S., Davids, M. S., Anderson, M. A., Guieze, R., Buccheri, V., Arrais-Rodrigues, C., Albareda, F. B., Clifford, R., Doubek, M., Jamroziak, K., Kater, A., Mattsson, M., Niemann, C., Pavlovsky, M., Scarfò, L., Walewska, R., Liu, P., Eom, K., Kreuzer, K., Tausch, E., Schneider, C., Stilgenbauer, S., Fischer, K., Hallek, M., Wu, K., Lefebure, M., Ding, W., Vezan, R., Eichhorst, B. (2025). A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL). Blood. https://doi.org/10.1182/blood-2025-2137